For the current week, the overall ratings of three pharmaceutical stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

VIVUS, Inc. (VVUS) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. For Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. As of Nov. 29, 2013, 30.9% of outstanding VIVUS, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VVUS stock.

Cempra, Inc. (CEMP) gets weaker ratings this week as last week’s C drops to a D. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. For a full analysis of CEMP stock, visit Portfolio Grader.

Corcept Therapeutics Incorporated. (CORT) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CORT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.